HeartFlow

Bottom line

HeartFlow delivers non-invasive fractional flow reserve (FFR) derived from coronary CT angiography (CCTA), enabling functional assessment of coronary stenoses without catheterization. The platform gained CPT code 75577 reimbursement in January 2026, a milestone that positions it as the only CCTA AI with explicit Medicare coverage for FFR-CT analysis. This makes HeartFlow a financially viable option for health systems already performing high-volume CCTA, particularly those seeking to reduce downstream invasive angiography referrals.

HeartFlow targets cardiologists, radiologists, and cardiovascular imaging centers managing stable chest pain or suspected coronary artery disease. The per-study reimbursement model aligns incentives for payers and providers, but requires robust CCTA acquisition protocols and introduces a cloud-based analysis workflow with typical 24-hour turnaround. Vendor stability is strong, with an IPO filing in 2026 and over a decade of clinical validation, though the platform remains expensive for smaller practices without dedicated cardiovascular imaging infrastructure.

This is the right tool for health systems with established CCTA programs seeking to stratify patients before invasive procedures. It is not suitable for emergency settings, practices without advanced CT scanners, or clinicians expecting real-time results at the point of care. The evidence base is extensive, regulatory clearances are in place, and the reimbursement pathway is clear. For organizations that fit the use case, HeartFlow represents one of the most defensible AI investments in cardiovascular imaging.

Why we picked it

HeartFlow stands apart in the CCTA AI landscape because it delivers functional coronary assessment that is both clinically validated and reimbursable. Most CCTA AI tools focus on anatomic plaque characterization, calcium scoring, or stenosis quantification. HeartFlow goes further by computing FFR-CT, a physiologic metric that predicts whether a given coronary lesion causes ischemia. This distinction matters clinically because anatomic stenosis severity correlates poorly with functional significance. A 60 percent stenosis on CCTA may or may not require intervention, but an FFR-CT value below 0.80 provides actionable guidance for revascularization decisions.

The CPT code 75577, effective January 2026, grants HeartFlow explicit reimbursement from Medicare and most commercial payers. This is rare among AI tools in radiology, where many products remain bundled into existing imaging codes or require justification as quality improvement add-ons. Reimbursement transforms HeartFlow from a nice-to-have into a revenue-neutral or revenue-positive investment for health systems, assuming adequate case volume. The clinical evidence supporting this reimbursement is robust, with multiple randomized trials and observational studies demonstrating that FFR-CT-guided care reduces unnecessary catheterizations and improves patient outcomes compared to CCTA alone.

HeartFlow also addresses a well-defined clinical gap. Invasive FFR during catheterization is the gold standard for functional assessment, but it requires arterial access, contrast, radiation, and procedural risk. Many patients with intermediate CCTA findings undergo invasive angiography only to learn that revascularization is not indicated. HeartFlow eliminates this step for a meaningful proportion of patients, reducing costs, procedural complications, and patient anxiety. The platform integrates plaque analysis alongside FFR-CT, providing a comprehensive coronary risk profile from a single CCTA dataset.

Vendor maturity matters when deploying AI in clinical workflows. HeartFlow has been commercially available since 2014, holds FDA De Novo clearance and CE-IVDR certification, and filed for IPO in 2026. This longevity suggests operational stability and sustained clinical adoption. The company has published extensively in peer-reviewed journals, collaborated with major health systems, and maintained partnerships with EHR vendors and radiology PACS platforms. These factors reduce the risk of vendor failure, product abandonment, or regulatory setbacks that plague early-stage medical AI companies.

What it does well

HeartFlow excels at translating CCTA datasets into actionable physiologic information. The core technology uses computational fluid dynamics to model blood flow through coronary arteries, simulating the pressure gradients that define FFR. This analysis runs on vendor-managed cloud infrastructure, leveraging proprietary algorithms trained on thousands of cases and validated against invasive FFR measurements. The output includes a three-dimensional color-coded coronary tree with FFR values at each vessel segment, plaque burden quantification, and stenosis severity grading. Radiologists and cardiologists receive a structured report that integrates seamlessly into clinical decision-making.

The platform reduces unnecessary invasive procedures. In the PLATFORM trial, FFR-CT-guided evaluation led to a 61 percent reduction in invasive coronary angiography without obstructive disease compared to standard care. This finding has been replicated across multiple health systems, demonstrating that FFR-CT identifies patients who can safely defer catheterization. For hospitals managing chest pain pathways, this translates into lower procedural costs, reduced cath lab utilization, and improved patient satisfaction. The economic case is particularly strong in settings with high volumes of intermediate-risk CCTA findings.

HeartFlow integrates plaque characterization alongside functional assessment. The HeartFlow Plaque Analysis module quantifies total plaque volume, calcified plaque, non-calcified plaque, and low-attenuation plaque, all of which correlate with adverse cardiovascular events. This dual capability allows clinicians to assess both current ischemia risk and long-term atherosclerotic burden from a single CCTA scan. The plaque metrics inform medical therapy decisions, lipid management, and lifestyle counseling in ways that FFR-CT alone does not address. This combination of functional and anatomic data is unique among CCTA AI tools.

The reimbursement pathway is transparent and established. CPT code 75577 covers HeartFlow FFR-CT analysis, with Medicare paying approximately 200 to 300 dollars per study depending on facility and professional components. Commercial payers generally follow Medicare coverage policies, though some require prior authorization or restrict use to specific clinical indications. The per-study billing model simplifies financial forecasting for health systems, as revenue is directly tied to case volume. This contrasts with subscription-based AI tools where ROI depends on uncertain utilization rates and productivity gains.

Where it falls short

HeartFlow requires high-quality CCTA acquisition, and not all scans qualify for analysis. The vendor specifies strict imaging protocol requirements, including sub-millimeter slice thickness, adequate contrast opacification, minimal motion artifact, and heart rate control. Scans acquired on older CT scanners or without beta-blocker premedication often fail quality thresholds, forcing re-scanning or rendering FFR-CT unavailable. This creates workflow friction, particularly in community hospitals or outpatient imaging centers without dedicated cardiovascular CT protocols. The vendor provides acquisition guidelines, but compliance is inconsistent, and rejected scans represent wasted time and patient radiation exposure.

Turnaround time is a limitation for time-sensitive decisions. HeartFlow analysis is performed off-site on vendor cloud infrastructure, with typical turnaround of 12 to 24 hours. This delay is acceptable for elective chest pain evaluation but precludes use in emergency department triage, acute coronary syndrome workup, or intraoperative decision support. Radiologists and cardiologists accustomed to real-time AI tools, such as automated calcium scoring or stenosis quantification, may find the cloud-based workflow disruptive. The platform does not support on-premises processing, so institutions with data sovereignty concerns or limited internet bandwidth face additional hurdles.

The per-study cost is non-trivial even with reimbursement. While CPT code 75577 covers the analysis, health systems must still pay HeartFlow upfront, typically several hundred dollars per study, before receiving payer reimbursement. The net margin depends on payer mix, contract rates, and whether the facility bills both technical and professional components. Smaller practices or those with high uninsured patient populations may find the economics unfavorable. Additionally, the reimbursement pathway does not cover all clinical indications, and off-label use, such as serial FFR-CT monitoring or research applications, requires out-of-pocket payment.

HeartFlow is a single-vendor cloud dependency. The platform does not offer on-premises deployment, white-label licensing, or integration with open-source CCTA analysis tools. Health systems commit to a long-term relationship with HeartFlow, trusting the vendor to maintain infrastructure uptime, data security, and algorithm performance. If HeartFlow experiences financial instability, regulatory challenges, or competitive pressure, customers have limited recourse. The 2026 IPO filing suggests stability, but publicly traded medical AI companies face earnings pressures that can lead to price increases, service reductions, or product pivots. The lack of vendor-neutral alternatives for FFR-CT analysis amplifies this risk.

Deployment realities

Deploying HeartFlow requires coordination between radiology, cardiology, and IT teams. The technical integration involves connecting the hospital PACS to HeartFlow's cloud platform via secure DICOM upload. Most modern PACS systems support this workflow, but older installations may require middleware or manual DICOM export. IT departments must approve cloud data transmission, ensure HIPAA-compliant encryption, and configure firewall rules to allow HeartFlow's servers to receive studies and return results. This process typically takes two to four weeks, assuming no institutional barriers to cloud-based clinical tools.

Radiologist and cardiologist training is essential. Interpreting FFR-CT results requires understanding the physiologic basis of fractional flow reserve, recognizing artifacts in the three-dimensional coronary models, and integrating FFR-CT values with plaque analysis and clinical context. HeartFlow provides online training modules, live webinars, and case interpretation guides, but proficiency develops over dozens of cases. Institutions should plan for a ramp-up period during which clinicians consult with HeartFlow clinical specialists or peer experts. Without structured training, there is risk of misinterpretation, over-reliance on FFR-CT thresholds, or failure to recognize scan quality issues that invalidate results.

Change management extends beyond the radiology department. Referring cardiologists, primary care physicians, and emergency department clinicians must understand when to order CCTA with FFR-CT, how to interpret reports, and how to act on results. This requires institutional protocols, order set modifications, and physician education. Health systems that successfully deploy HeartFlow often establish dedicated chest pain pathways or cardiovascular imaging centers where FFR-CT is embedded in standardized care algorithms. Ad hoc adoption without clear clinical pathways leads to underutilization, inconsistent ordering, and poor return on investment.

Pricing realities

HeartFlow operates on a per-study fee-for-service model, with health systems paying the vendor upfront and seeking reimbursement from payers. The vendor does not publish fixed pricing, but market intelligence suggests fees in the range of 400 to 800 dollars per FFR-CT analysis, depending on contract volume and institutional negotiations. This cost is offset by CPT code 75577 reimbursement, which Medicare pays at approximately 200 to 300 dollars for the professional and technical components combined. The net margin depends on payer contracts, with commercial insurers often reimbursing at higher rates than Medicare.

Hidden costs include re-scanning for rejected studies, IT integration fees, and training time. If 10 to 20 percent of submitted CCTA scans fail quality thresholds, the effective cost per successful FFR-CT analysis rises accordingly. Some institutions pay for repeat CCTA acquisitions with optimized protocols, adding patient radiation exposure and technologist time. Additionally, health systems with high uninsured or underinsured patient populations may absorb unreimbursed HeartFlow fees, eroding the financial case. Contract terms typically require annual commitments, and volume-based discounts incentivize high utilization, which may not align with clinical need.

The ROI calculation hinges on avoided downstream costs. If HeartFlow prevents one invasive angiography per three FFR-CT studies, and invasive angiography costs 5000 to 10000 dollars per procedure, the savings exceed the HeartFlow fee. However, this math assumes that avoided catheterizations would have occurred without FFR-CT guidance, which is difficult to prove retrospectively. Health systems should model expected case mix, payer reimbursement rates, and current catheterization volumes before committing to HeartFlow. The financial case is strongest for high-volume cardiovascular imaging centers with favorable payer contracts and established chest pain pathways.

Compliance + integration depth

HeartFlow holds FDA De Novo clearance (Class II device) for FFR-CT analysis, granted in 2014 and updated with subsequent plaque analysis modules. The FDA clearance covers coronary artery disease assessment in patients with stable chest pain or equivalent symptoms, using CCTA datasets acquired according to specified imaging protocols. The platform also holds CE-IVDR certification for the European market, demonstrating compliance with the EU Medical Device Regulation. These clearances provide regulatory assurance, but they do not extend to off-label use cases such as acute coronary syndrome, serial monitoring, or research applications.

HIPAA compliance is vendor-managed. HeartFlow's cloud infrastructure is SOC 2 Type II certified, encrypts data in transit and at rest, and implements business associate agreements (BAAs) with customer health systems. The vendor maintains detailed audit logs, supports breach notification procedures, and undergoes third-party security assessments. However, health systems remain the covered entities under HIPAA, meaning institutional privacy officers must review HeartFlow's data handling practices, ensure patient consent for off-site analysis, and verify that DICOM uploads do not include protected health information beyond what is necessary for FFR-CT computation.

EHR integration depth varies by platform. HeartFlow does not directly write results into EHR flowsheets or clinical decision support modules. Instead, the FFR-CT report is delivered as a PDF and DICOM structured report, which can be attached to the patient chart or viewed in the PACS. Some health systems configure HL7 interfaces to auto-import HeartFlow reports into Epic or Cerner, but this requires custom integration work. The lack of native EHR interoperability means that clinicians must manually review reports rather than having FFR-CT values surface automatically in order sets or risk calculators. This is a missed opportunity for workflow integration and clinical decision support.

Vendor stability + roadmap

HeartFlow filed for IPO in 2026, signaling financial maturity and investor confidence. The company has raised over 500 million dollars across multiple funding rounds, with backers including major venture capital firms and strategic investors from the cardiovascular device industry. This capital base supports continued algorithm development, clinical trial sponsorship, and international expansion. The IPO filing includes detailed financials, customer counts, and growth projections, providing transparency that private-stage medical AI companies rarely offer. Publicly traded status introduces quarterly earnings pressures, but it also subjects HeartFlow to rigorous financial disclosure and governance standards.

The customer base includes major academic medical centers and integrated delivery networks. HeartFlow has published case studies and testimonials from institutions such as Cleveland Clinic, Mayo Clinic, and Stanford Health Care, demonstrating adoption among opinion leaders in cardiovascular imaging. The vendor maintains partnerships with CT scanner manufacturers, PACS vendors, and cardiovascular specialty societies, all of which expand market reach and validate clinical utility. The length of commercial availability, over a decade, suggests that the product has survived the valley of death that claims many early-stage medical AI startups.

The roadmap likely includes expanded plaque analysis, AI-enhanced coronary risk scoring, and integration with longitudinal patient data. HeartFlow has published research on predicting future cardiovascular events based on plaque morphology and FFR-CT values, suggesting that the platform may evolve from a diagnostic tool into a prognostic risk stratification system. The vendor has also hinted at expanding beyond coronary arteries into peripheral vascular and structural heart applications, though these remain investigational. Health systems investing in HeartFlow should expect iterative product updates, regulatory submissions for new indications, and potential price adjustments as the company optimizes for profitability post-IPO.

How it compares

Cleerly is the closest competitor, offering AI-powered plaque analysis from CCTA but without FFR-CT capability. Cleerly quantifies plaque burden, characterizes plaque composition, and generates atherosclerotic cardiovascular disease risk scores, but it does not compute fractional flow reserve. This makes Cleerly better suited for long-term risk stratification and preventive cardiology, while HeartFlow excels at immediate revascularization decision support. Some institutions deploy both tools in complementary roles, using Cleerly for screening and HeartFlow for intermediate-stenosis evaluation. Cleerly has also filed for FDA clearance and is pursuing CPT code reimbursement, so the competitive landscape may shift if Cleerly gains payer coverage for plaque analysis.

CathWorks FFRangio computes FFR from invasive coronary angiography rather than CCTA. FFRangio is a cath lab tool that provides real-time functional assessment during coronary angiography, eliminating the need for pressure wire-based invasive FFR measurement. This positions FFRangio as a procedural aid rather than a pre-procedural planning tool. HeartFlow and FFRangio serve different stages of the care pathway: HeartFlow helps decide whether to catheterize at all, while FFRangio helps decide whether to stent once the patient is already in the cath lab. The two products do not compete directly, and some health systems use both.

Circle Cardiovascular Imaging and Siemens Healthineers AI-Rad Companion Cardiovascular offer automated CCTA analysis but focus on stenosis quantification, calcium scoring, and vessel segmentation rather than FFR computation. These tools are faster and cheaper than HeartFlow, with on-premises deployment options and real-time results, but they provide only anatomic assessment. For patients with clearly obstructive or clearly non-obstructive disease on CCTA, these tools may suffice. For intermediate stenoses where functional significance is uncertain, HeartFlow's FFR-CT capability justifies the added cost and turnaround time. The choice depends on case mix and institutional care pathways.

No other vendor currently offers reimbursable FFR-CT analysis under CPT code 75577. This gives HeartFlow a regulatory and financial moat that competitors cannot easily replicate. Building a competitive FFR-CT platform requires extensive clinical validation, FDA clearance, payer negotiations, and computational infrastructure, all of which take years. HeartFlow's first-mover advantage and entrenched relationships with payers and health systems make it the de facto standard for CCTA-derived FFR. Competitors may enter the market, but HeartFlow's head start is substantial.

What clinicians say

Clinician feedback on HeartFlow is sparse in publicly accessible forums. A search of Reddit discussions in r/medicine, r/cardiology, and r/radiology identified only one mention, in which a cardiologist described HeartFlow as useful for avoiding unnecessary catheterizations in patients with intermediate CCTA findings. The commenter noted that FFR-CT results sometimes surprised them, revealing functional significance in lesions that appeared mild anatomically, and vice versa. This anecdote aligns with published trial data but represents a single data point rather than a representative sample.

The thin social media footprint likely reflects HeartFlow's niche positioning within cardiovascular imaging subspecialties. Most primary care physicians, hospitalists, and even general cardiologists do not directly interact with HeartFlow, as the tool is typically operated by radiologists or advanced imaging cardiologists. The lack of widespread discussion does not imply dissatisfaction, but it does mean that prospective buyers should seek references from peer institutions rather than relying on crowdsourced opinions. Vendor-provided case studies and testimonials are available, but these are curated and should be interpreted with appropriate skepticism.

Health systems considering HeartFlow should conduct site visits, interview radiology and cardiology colleagues at existing customer institutions, and request data on scan rejection rates, turnaround times, and reimbursement capture. The limited public discourse on HeartFlow underscores the importance of due diligence and pilot testing before committing to long-term contracts.

What the literature says

HeartFlow has extensive peer-reviewed validation. A 2026 meta-analysis in Open Heart assessed the prognostic value of FFR-CT for major adverse cardiovascular events in patients with suspected or known coronary artery disease. The study pooled data across multiple cohorts and confirmed that FFR-CT stratifies risk, with low FFR-CT values predicting higher event rates and guiding revascularization decisions. This meta-analysis reinforces the clinical utility of FFR-CT beyond diagnostic accuracy, positioning it as a tool for long-term risk management rather than just anatomic assessment.

A 2024 observational study in Radiology Cardiothoracic Imaging compared HeartFlow's AI-enabled plaque quantification against intravascular ultrasound (IVUS), the gold standard for plaque burden measurement. The study found strong correlation between HeartFlow plaque volumes and IVUS-derived measurements, validating the accuracy of the AI-based plaque analysis module. This evidence supports the dual use of HeartFlow for both functional assessment (FFR-CT) and anatomic plaque characterization, strengthening the value proposition for institutions seeking comprehensive coronary evaluation from a single CCTA dataset.

Three additional publications in 2025 discussed HeartFlow in the context of broader AI applications in cardiovascular imaging. A review in Discoveries (Craiova) summarized the current landscape of AI in CV imaging, highlighting HeartFlow as a leading example of commercially successful AI with FDA clearance and clinical adoption. A second review in International Journal of Cardiovascular Imaging explored AI's role in chronic total occlusion management and mentioned HeartFlow as a potential planning tool for complex interventions. A third review in Cureus discussed AI in precision cardiovascular medicine, citing HeartFlow's FFR-CT as an exemplar of how AI can augment physiologic assessment.

The literature base is robust by medical AI standards, with randomized trials, real-world observational studies, and systematic reviews all supporting HeartFlow's clinical validity. The evidence quality is sufficient to justify CPT code reimbursement and institutional adoption. However, most studies are sponsored or co-authored by HeartFlow employees, which is common in medical device research but introduces potential bias. Independent real-world effectiveness studies from non-vendor-affiliated health systems would strengthen the evidence base further.

Who it's for

HeartFlow is best suited for health systems with high-volume cardiovascular CT programs managing stable chest pain or suspected coronary artery disease. The ideal customer is an academic medical center or large integrated delivery network with dedicated cardiovascular imaging radiologists, interventional cardiologists, and established chest pain pathways. These institutions have the case volume to justify per-study fees, the technical infrastructure to integrate cloud-based workflows, and the clinical expertise to interpret FFR-CT results appropriately. The reimbursement model works when the facility bills both technical and professional components and maintains favorable payer contracts.

Outpatient imaging centers and community hospitals with advanced CT scanners can also benefit, provided they have radiology support for CCTA protocol optimization and cardiology colleagues who will act on FFR-CT results. Smaller practices without in-house cardiology or those performing fewer than 50 CCTA scans per month may struggle to achieve economies of scale. The upfront per-study cost and rejected scan risk make low-volume adoption financially marginal. Rural hospitals and critical access hospitals are unlikely to find HeartFlow cost-effective unless they participate in regional cardiovascular networks that centralize CCTA interpretation.

HeartFlow is not for emergency departments seeking real-time coronary assessment, as the 12- to 24-hour turnaround precludes use in acute settings. It is not for institutions without high-quality CT scanners or those unable to implement strict CCTA acquisition protocols. It is not for practices that rely heavily on uninsured or Medicaid patient populations where reimbursement is uncertain. Solo cardiologists, telemedicine-only practices, and international markets without CPT code 75577 coverage should evaluate alternatives or negotiate custom pricing with the vendor.

The verdict

HeartFlow is the most clinically validated and financially viable CCTA AI tool for functional coronary assessment. The CPT code 75577 reimbursement pathway, FDA De Novo clearance, and extensive peer-reviewed evidence base make it a defensible investment for health systems with established cardiovascular imaging programs. The platform addresses a real clinical gap by reducing unnecessary invasive angiography, improving patient outcomes, and generating actionable physiologic data from non-invasive CCTA. The vendor's IPO filing and decade-long commercial track record provide confidence in long-term stability.

However, HeartFlow is not a universal solution. The per-study cost, cloud-based turnaround time, strict imaging protocol requirements, and dependence on a single vendor limit its applicability. Institutions should pilot HeartFlow with a defined patient cohort, measure scan rejection rates and reimbursement capture, and assess workflow integration before committing to multi-year contracts. The thin clinician feedback footprint on public forums underscores the importance of peer references and site visits. The evidence base, while strong, is heavily vendor-sponsored, and independent real-world effectiveness studies would strengthen confidence.

If your institution performs high-volume CCTA, manages stable chest pain pathways, and seeks to reduce downstream catheterization costs, HeartFlow is the right choice. If you need real-time coronary assessment, lack advanced CT infrastructure, or serve primarily uninsured populations, look elsewhere. For most academic medical centers and large health systems with cardiovascular imaging capabilities, HeartFlow represents one of the most evidence-backed AI investments in radiology. The reimbursement pathway, clinical validation, and vendor maturity justify adoption, provided the deployment realities and cost structure align with institutional priorities.